|
|
|
|
Vol. 59, Issue 5, 1333-1342, May 2001
v
3 Blockade of Endothelial
Cells
Departments of Pharmacology (C.-H.Y., H.-C.P., T.-F.H) and
Orthopedics (R.-S.Y.), College of Medicine, National Taiwan University,
Taipei, Taiwan.
Angiogenesis consists of the proliferation, migration, and
differentiation of endothelial cells, although angiogenic factor and
integrin-extracellular matrix interaction modulate this process. We
report here that a snake venom-derived disintegrin, rhodostomin, inhibited distinct steps in angiogenesis elicited by basic fibroblast growth factor (bFGF), and also suppressed in vivo murine melanoma tumor
growth. Rhodostomin dose-dependently inhibited bFGF-induced human
umbilical vein endothelial cell (HUVEC) proliferation as examined by
cell number count, metabolic activity, and BrdU incorporation assays
with submicromolar IC50 values. However, it apparently did
not affect the viability of murine B16F10 melanoma cells, even up to 50 µM. Rhodostomin also inhibited HUVEC migration and invasion evoked by
bFGF, and tube formation of bFGF-treated HUVECs in Matrigel. Moreover,
rhodostomin selectively inhibited bFGF-, but not vascular endothelial
growth factor-associated angiogenesis in the chick chorioallantoic
membrane model. Furthermore, rhodostomin blocked both bFGF- and
B16F10-induced neovascularization in murine Matrigel plug model and
suppressed the growth of subcutaneously inoculated B16F10 solid tumor,
leading to a prolonged survival of the rhodostomin-treated C57BL/6
mice. The antiangiogenic effect of rhodostomin on bFGF-treated HUVECs
is related to the integrin
v
3 blockade,
as evidenced by its selective inhibition on the binding of 7E3, a
monoclonal antibody (mAb) raised against
v
3, but not that of P1F6, an
v
5 mAb toward both naive and bFGF-primed HUVECs. Moreover, 7E3 specifically blocked fluorescein
isothiocyanate-conjugated rhodostomin binding to HUVEC, whereas P1F6
and anti-integrin
2,
3,
4,
or
5 mAbs did not.
This article has been cited by other articles:
![]() |
M. Philippova, A. Banfi, D. Ivanov, R. Gianni-Barrera, R. Allenspach, P. Erne, and T. Resink Atypical GPI-Anchored T-Cadherin Stimulates Angiogenesis In Vitro and In Vivo Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2222 - 2230. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. W. Ashton, Y. Cheng, A. Helisch, and J. A. Ware Thromboxane A2 Receptor Agonists Antagonize the Proangiogenic Effects of Fibroblast Growth Factor-2: Role of Receptor Internalization, Thrombospondin-1, and {alpha}v{beta}3 Circ. Res., April 2, 2004; 94(6): 735 - 742. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Trochon-Joseph, D. Martel-Renoir, L. M. Mir, A. Thomaidis, P. Opolon, E. Connault, H. Li, C. Grenet, F. Fauvel-Lafeve, J. Soria, et al. Evidence of Antiangiogenic and Antimetastatic Activities of the Recombinant Disintegrin Domain of Metargidin Cancer Res., March 15, 2004; 64(6): 2062 - 2069. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wang, J. J. Ubl, R. Stricker, and G. Reiser Thrombin (PAR-1)-induced proliferation in astrocytes via MAPK involves multiple signaling pathways Am J Physiol Cell Physiol, November 1, 2002; 283(5): C1351 - C1364. [Abstract] [Full Text] [PDF] |
||||